Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.67 |
| ▸ | CA12 | O43570 | 8/20 | 0.60 |
| ▸ | CA2 | P00918 | 5/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 7/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.38 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3349991 | 0.97 | CA1 (0.63) | CA1CA12CA2CA14CA9 | |
| SCHEMBL14229365 | 0.89 | CA1 (0.55) | CA1CA12CA2CA14CA9 | |
| SCHEMBL28163257 | 0.88 | CA1 (0.60) | CA1CA12CA2CA14CA9 | |
| SCHEMBL27973878 | 0.85 | CA1 (0.57) | CA1CA12CA2CA14CA9 | |
| SCHEMBL7247026 | 0.84 | CA1 (0.63) | CA1CA12CA2CA14CA9 | |
| SCHEMBL2885118 | 0.83 | CA1 (0.55) | CA1CA12CA2CA14CA9 | |
| SCHEMBL6547381 | 0.83 | CA1 (0.55) | CA1CA12CA2CA14CA9 | |
| SCHEMBL2885120 | 0.83 | CA12 (0.56) | CA1CA12CA2CA14CA9 | |
| SCHEMBL14200184 | 0.83 | CA1 (0.48) | CA1CA12CA2CA14CA9 | |
| SCHEMBL14229362 | 0.81 | CA1 (0.46) | CA1CA12CA2CA14CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103911615-B | Etching agent composite for copper-containing metal | 东友精细化工有限公司 | 2017-08-22 | — | — | CN | claimed |
| CN-103911615-A | Etching agent composition used for copper-contained metal | DONGWOO FINE CHEM CO LTD | 2014-07-09 | — | — | CN | claimed |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | claimed |
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | claimed |
| CN-1732161-A | 1,3-diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARM INC (US) | 2006-02-08 | — | — | CN | claimed |
| EP-1565428-A1 | SUBSTITUTED UREAS AND CARBAMATES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | claimed |
| EP-1534693-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2004050609-A1 | SUBSTITUTED UREAS AND CARBAMATES | ELAN PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| WO-2004022523-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| EP-3710449-B1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | BROAD INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-103911615-B | Etching agent composite for copper-containing metal | 东友精细化工有限公司 | 2017-08-22 | — | — | CN | disclosed |
| CN-103911615-A | Etching agent composition used for copper-contained metal | DONGWOO FINE CHEM CO LTD | 2014-07-09 | — | — | CN | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | disclosed |
| CN-1732161-A | 1,3-diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARM INC (US) | 2006-02-08 | — | — | CN | disclosed |
| EP-1565428-A1 | SUBSTITUTED UREAS AND CARBAMATES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050609-A1 | SUBSTITUTED UREAS AND CARBAMATES | ELAN PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | BACE1, APP, BACE2 | CA1 1011/4885CA12 4081/4885CA2 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.